We subsequently developed a more distinct probe, [18F]CFA, which was used in The existing review to evaluate dCK action in tumors when treated with a little molecule dCK inhibitor. This probe is additionally staying examined inside of a clinical demo at our institution To guage adjustments in dCK activity following most cancers immunotherapy 18. PE